	US 11,654,181 B2
	Use of CXCL12 for therapy after prostate surgery
James K. Williams, Clemmons, NC (US)
Assigned to Wake Forest University Health Sciences, Winston-Salem, NC (US)
Appl. No. 16/637,498
Filed by Wake Forest University Health Sciences, Winston-Salem, NC (US)
PCT Filed Aug. 10, 2018, PCT No. PCT/US2018/046156 § 371(c)(1), (2) Date Feb. 7, 2020, PCT Pub. No. WO2019/032930, PCT Pub. Date Feb. 14, 2019.
Claims priority of provisional application 62/544,176, filed on Aug. 11, 2017.
Prior Publication US 2020/0215160 A1, Jul. 9, 2020
Int. Cl. A61K 38/19 (2006.01); A61P 15/10 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01)

CPC A61K 38/195 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0031 (2013.01); A61K 9/0034 (2013.01); A61P 15/10 (2018.01); A61K 48/00 (2013.01)]

16 Claims

1. A method of treating a male subject that has undergone prostate surgery for urological symptoms from the surgery, said method comprising administering wild-type CXCL12 protein to the subject in a treatment-effective amount,

wherein said symptoms comprise erectile dysfunction,

wherein said CXCL12 protein is administered within a time frame of from one month to six months after said prostate surgery, and

wherein the administering is carried out by locally administering the CXCL12 protein at two or more sites at or near the site of the prostate surgery.